Clinical validation of pneumatic transportation systems for monoclonal antibodies

- 3 Pierre Coliat^{1*}, Stéphane Erb^{2,3,4}, Hélène Diemer^{2,3,4}, Dan Karouby¹, Mainak Banerjee¹, Chen
- 4 Zhu¹, Martin Demarchi¹, Sarah Cianférani^{2,3,4#}, Alexandre Detappe^{1,2,3#}, Xavier Pivot^{1#}
- 5 1. Institut de Cancérologie Strasbourg Europe, Strasbourg, France
- 6 2. Institut Pluridisciplinaire Hubert Curien, CNRS UMR7178, Université de Strasbourg,
- 7 Strasbourg, France
- 8 3. Institut du Médicament Strasbourg, Strasbourg, France
- 9 4. Infrastructure Nationale de Protéomique ProFI FR2048, Strasbourg, France
- 10
- 11 * Corresponding author:
- 12 Pierre COLIAT (p.coliat@icans.eu)
- 13 ICANS, 17 Rue Albert Calmette Strasbourg
- 14 # contributed equally
- 15
- 16 Keywords: pneumatic tube system, stressed antibodies, stability
- 17
- 18 Word count: 4079 words

20 Abstract: Pneumatic transportation systems (PTS) were recently proposed as a method to carry ready-for-injection diluted monoclonal antibodies (mAbs) from the pharmacy to the bedside of 21 22 patients. This method reduces transportation time and improves the efficiency of drug distribution process. However, mAbs are highly sensitive molecules for which subtle alterations may lead to 23 deleterious clinical effects. These alterations can be caused by various external factors such as 24 25 temperature, pH, pressure, and mechanical forces that may occur during transportation. Hence, it 26 is essential to ensure that the mAbs transported by PTS remain stable and active throughout the 27 transportation process. This study aims to determine the safety profile of PTS to transport 11 28 routinely used mAbs in a clinical setting through assessment of critical guality attributes (CQA) and orthogonal analysis. Hence, we performed aggregation/degradation profiling, post-29 30 translational modifications identification using complementary mass spectrometry-based 31 methods, along with visible and subvisible particle formation determination by light absorbance 32 and dynamic light scattering measurements. Altogether, these results highlight that PTS can be 33 safely used for this purpose when air is removed from the bags during preparation.

34 Introduction

Over the past two decades, numerous therapeutic breakthroughs in oncology have been achieved with monoclonal antibodies (mAbs). These mAbs were developed and approved either as modulators of the oncogenic signaling pathway by targeting overexpressed receptors (*e.g.* trastuzumab and pertuzumab for ErbB2, cetuximab and panitumumab for ErbB1), as a trap of soluble ligands involved in angiogenesis (bevacizumab for VEGFA), or as immunomodulators by inhibiting immune checkpoints (pembrolizumab, atezolizumab, nivolumab, avelumab, and durvalumab for the PD-1/PD-L1 pathway, ipilimumab for the CTLA-4 pathway).

Unlike conventional small molecule chemotherapies, the intricate structures of mAbs make them susceptible to chemical modifications under conditions of chemical or physical stress¹. Among chemical instabilities, methionine, histidine, and cysteine are known to cause changes in protein structure, potentially leading to oxidation and the formation of disulfide bonds². Presence of deamidation of glutamine and asparagine can induce changes in the structure of the protein; as a result, the fragmentation of disulfide bonds may dissociate the mAbs structure and lead to an inactive product³.

49 The physical instabilities are mainly characterized by reversible and nonreversible aggregations due to weak nonspecific bond formation¹. For those reasons, manufacturers need to perform 50 extensive stability studies on the final product as well as on its diluted version which is specifically 51 52 prepared for injection in a clinical setting to attain authorization for routine usage from regulatory agencies; these guidelines are well established and comparable worldwide^{4,5}. Diluted mAbs 53 products may undergo changing conditions; the reconstituted product contains lower 54 concentrations of stabilizers (*i.e.*, polysorbate 20, polysorbate 80) and additional excipients in the 55 56 solvent (*i.e.*, sodium chloride or dextrose). Thus, the manufacturers recommend that the product is administered within 24h after the dilution to minimize the risk of mAbs being altered.: In this 57 58 study, the container is a plastic bag instead of a glass vial which exhibits a wider air-liquid interface

that may induces aggregates and the formation of visible/subvisible particles due to the shaking 59 of the container during transportation⁶. In addition, several studies have demonstrated that the 60 61 lack of PS20 or PS80 increases the adhesion and aggregation of mAbs to the plastic bag in polyvinylchloride (PVC) or polyolefin^{7–9}. These 2 major mAbs modifications are considered risks. 62 as they may lead to immunogenicity¹⁰. The key critical guality attributes (CQAs) of mAbs, including 63 64 the protein structure or the glycosylation profile, can be altered but cause a risk of altered activity and/or toxicity^{11,12}: thus the conditions of preparation for mAbs must be considered with caution to 65 66 ensure that the administrated therapy is safe and effective.

67 One of the most common feature present in all major hospitals is the presence of pneumatic transportation systems (PTS). They were originally developed to accelerate the transportation 68 biological samples from one floor to another. More recently, they were deployed for the 69 70 transportation of anticancer therapies. According to each country, the regulations supporting the 71 routine use of PTS vary from a definitive prohibition guided by precautionary principles due to the 72 lack of robust evidence to a systematic utilization. These variable approaches and discrepancies 73 in the routine use of PTS occur because of the external stress applied to these mAbs during 74 transportation as they undergo acceleration and deceleration of multiple g forces as well as radical 75 gravity forces. Here, we sought to determine the possible alterations that occur in terms of CQA 76 to qualify the routine use of PTS with 11 mAbs approved for clinical use in oncology by the European Medicines Agency (EMA). 77

78

80 Results:

Characteristics of the PTS. The PTS from the Institut de Cancérologie Strasbourg Europe 81 82 (ICANS) is an Aerocom AC4000 160mm millimeters, 1000m long and includes approx. 20 curves 83 (Figure 1A-B). The cartridge used to transport the mAbs along the different departments from the 84 institution undergoes an acceleration profile of 4.06 ± 1.75 per travel with more than 15 85 acceleration peaks of >20g per travel and a maximum at 32g that is reached 4 times (Figure 1C). For this study, we placed the diluted mAbs inside the cartridge; the mAbs went through the whole 86 tube 1x to characterize the institution setup and 10x to generalize the results to almost any PTS 87 88 system installed in Europe using the same technical features.

89

Aggregation analysis. We assessed the potential aggregation by characterizing the high 90 molecular weight species (HMWS) and the degradation products by assessing the low molecular 91 weight species (LMWS) by size-exclusion chromatography coupled to native mass spectrometry 92 93 (SEC-nMS), a method that accurately quantifies HMWS/LMWS from SEC along with mass identification of each species within the same analysis^{13,14}. The SEC-nMS was used to evaluate 94 95 the HMWS and LMWS contained in the reference mAbs (non-diluted, in glass vial), post thermal 96 stress (20 days 40°C, non-diluted, in glass vial, see material and methods), and for the diluted 97 product passed 1-time in the PTS. We highlighted the results obtained with the mAb pertuzumab; 98 these results will be used as case study throughout the manuscript, additional mAbs are presented as bar graphs. The SEC-nMS reveals 3 peaks corresponding to the main monomeric drug product 99 (peak 2, MW 148,095 ± 2 Da, 99.8%), minor dimeric HMWS (peak 1, < 0.1%) and Fc-Fab LMWS 100 101 (peak 3, <0.1 %). Samples after 1 PTS passage exhibit superimposable SEC-UV and nMS profiles to the one of reference samples, while thermally stressed samples show significantly higher 102 103 amounts of both HMWS (dimers, 0.9%, p=0.027) and LMWS (100,941 ± 7 Da for Fc-Fab and $47,650 \pm 2$ Da for Fab fragments, 3.5% in total; p=0.0104) (Figure 2A-B). 104

For all mAbs, the main observed peak was attributed to the monomeric mAb drug product highlighting high levels of purity for reference mAbs (> 99.5%, **Figure 2C**). Only very minor species corresponding to the mAb aggregates (dimers ~300 kDa, < 0.3%) and fragments (Fab fragment ~47 kDa, < 0.1%) were quantified from SEC-UV data and online identified by nMS. Only two mAbs (panitumumab and bevacizumab) showed a higher content of HMWS (~1.1-1.2%) (**Figure 2C**), which is in agreement with literature data¹⁵.

111 After 1 PTS passage, chromatographic profiles were not significantly different from those of 112 reference samples, and the drug substance being detected as main product (> 99.5%) with minor 113 HMWS (<0.3%) and LMWS (<0.1%). The overall degradation profile was strongly affected upon 114 thermal stress (higher HWMS and/or LMWS) independently of the 11 mAb compared to PTS and reference samples, confirming that the thermal stress should be used as positive control for mAb 115 116 degradation¹⁶. Of interest, panitumumab, bevacizumab, trastuzumab, cetuximab and pertuzumab 117 are significantly less stable under thermal stress, leading to either higher amounts of HMWS (> 118 3%, panitumumab and bevacizumab) or LMWS (>2%, trastuzumab, pertuzumab, bevacizumab 119 and cetuximab).

Altogether, this study was performed with 11 diluted mAbs and demonstrated that neither reference mAbs, nor samples were degraded with one PTS passage in contrast to thermally stressed samples. They all exhibit comparable amounts of monomeric drug product (main peak), HMWS, and LMWS species confirming the safety profile of the PTS system from the ICANS institution. Similar results were obtained after 10 passages in the PTS for trastuzumab (**Figure S1**) confirming its safety profile.

126

Glycoprofiles and post translational modifications (PTMs). We next focused on glycoprofiles
 and some important PTMs which were defined as CQA (oxidations, N-terminal pyroglutamylation

and C-terminal lysine deletion) to further examine the impact due to PTS at the molecular level.
We combined complementary LC-MS methods in either native (SEC-nMS) or denaturing
(reversed-phase liquid chromatography, rpLC-MS) conditions at both intact mAb and subunit
levels (after IdeS digestion) to avoid extensive time-consuming peptide mapping (Figure 3).

Glycosylation is among the most common PTM that can induce tremendous effects on the physicochemical properties, structure, and function of mAbs therapeutic efficiency¹⁷. The glycoprofile can affect the absorption distribution metabolization elimination (ADME) properties and the biosimilarity of the glycoprotein-based drugs by altering the PK profile¹⁸, receptor binding, and antibody dependent cell cytotoxicity (ADCC)¹⁹. Currently, MS-based techniques are widely used for the analysis of mAb heterogeneity of glycosylation^{20,21}.

Glycoprofiles were first investigated using SEC-nMS on intact reference mAbs, after one PTS 139 passage and after thermal stress. The overlaid deconvoluted native mass spectra of the 3 different 140 141 pertuzumab samples (diluted, PTS, thermally stressed) demonstrates perfectly superimposable 142 glycoprofiles at the intact level and unambiguous mass identification of the main glycovariants (G0F/G0F, G1F/G0F, G1F/G1F and G2F/G1F) (Figure 3A-B). No peak broadening is observed 143 144 for the PTS samples in comparison to reference mAb conversely to thermally stressed samples. Among the 10 mAbs studied (atezolizumab being a-glycosylated), only cetuximab glycoprofiling 145 could not be tackled by SEC-nMS, in agreement with this mAb bearing two glycosylation sites^{22,23}. 146 No significant glycoprofiles differences were observed for any of the samples in the different 147 148 conditions (reference, PTS or thermally-stressed; p>0.05) (Figure 3C).

To cross validate the SEC-nMS results, the middle-up analysis of all mAbs were performed after ldeS digestion using a more classical high resolution rpLC-MS method on ~25 kDa subunits²⁴. Three main peaks are observed for pertuzumab, corresponding to Fc/2 (peak 2, 25236 Da), LC (peak 3, 23526), and Fd (peak 3, 25315) subunits respectively. The Fc/2 part bearing the Nglycosylation pattern (Man5, G0F-GlcNAc, G0, G0F, G1F, G2F) (**Figure 4**). The rpLC chromatogram of reference and PTS samples present similar patterns, whereas the peak 1 is more intense in the thermally stressed sample. Similar to the intact mass analysis, Fc/2 glycoprofiles of reference versus PTS or temperature stressed samples overlay perfectly.

The glycoprofiles observed for all 10 other mAbs were non-significantly different (**Figure 5**), suggesting that the glycoprofiles are not significantly affected upon PTS passage (p>0.05). Interestingly, bevacizumab undergoes loss of G0F upon thermal stress. This result is in accordance with knowledge that this mAb is more prone to stress conditions than other mAbs.

161

162 K-clipping. The presence/absence of C-terminal lysine (K-clipping) in the heavy chain (Fc fragment) is another common CQA that reflects the manufacturing consistency. This modification 163 can be assessed by rpLC-MS at the middle level as it generates a mass shift of ~128 Da (K 164 165 clipping/deletion variant) and a more hydrophobic variant. Among the 11 mAbs studied, rpLC-MS 166 analysis of the Fc subunit revealed that all of them are formulated in their fully K-clipped versions (>95%, total Fc-K species, Table 3), while proteoforms containing the C-terminal lysine 167 168 representing <5% in diluted mAb samples (**Table 3**). Cetuximab and avelumab are examples of mAbs exhibiting mixtures of K-clipped (~75%) and non-K-clipped (~25%) forms. Importantly, the 169 170 ratio of K-clipped/K-containing species remains unchanged after 1 PTS passage (Table 3). Similar 171 conclusions can be drawn from thermally stressed samples, suggesting that deletion of C-terminal 172 lysine is stable once generated from the production process and not significantly impacted upon any of the stress conditions. 173

174

Oxidation. Oxidation is an important CQA that impacts the structural integrity, conformational stability, safety, and efficacy of the mAb product²⁵. While no negative impacts have been reported for the oxidation present on complementary determining regions (CDR) on antigen binding, many negative impacts have been reported for the oxidation of Met residues in the Fc part of the mAb

such as decreased thermal stability, increased aggregation, decreased complement dependent 179 180 cytotoxicity (CDC), decreased binding affinity to neonatal Fc receptor (FcRn), and shorter in vivo 181 half-life, etc. We thus sought to explore to which extend PTS passages could induce mAb oxidation 182 (+16 or 32 Da mass increases), knowing that limited effects are expected as air was removed from the plastic packaging. No oxidation was detected on the Fc or Fd subunits of the reference mAbs. 183 184 at the exception of atezolizumab and bevacizumab for which traces were observed (<3%, **Table** 3). Importantly, these levels were not affected post PTS passage, but were observed for the 185 186 thermally stressed mAbs (e.g. atezolizumab Fd, bevacizumab Fc+Fd, Table 3).

187

188 **Pyro-Glu**. N-terminal pyroglutamate (pyroGlu) is a common mAb modification that mainly results from a non-enzymatic cyclization of N-terminal glutamine (Gln) or to a much lower extent from the 189 conversion of N-terminal glutamate (Glu) into pyroGlu²⁶. Cyclization of N-terminal Gln/Glu to 190 191 pyroGlu reduces the molecular weight of a mAb by 17 Da or 18 Da, respectively and induces more acidic variants compared to original non-N-terminally modified mAbs²⁰. However, the presence of 192 193 N-terminal pyroGlu exhibits no direct impact on mAb structure and function. As levels of N-terminal 194 pyroGlu observed in mAbs vary strongly with various environmental factors (buffer composition. pH, temperature during cell culture and purification, etc.), we next investigated the N-terminal 195 196 cyclization on the Fd subunit of the 11 mAbs (Table 3). Half of them were formulated as nonpyroGlu forms and very low levels (<3%) of pyroGlu modification on the N-terminal part of our 197 198 mAbs were detected. At the opposite, the other mAbs are formulated as pyroglutamylated forms 199 (>93%, Table 3), except for panitumumab formulated as a mixture of unmodified (21%) and Nterminal pyroGlu (79%) forms. No significant changes were detected after PTS passage, while 200 201 increased level of pyroGlu forms are systematically observed upon thermal stress (Table 3).

202

204 Visible and subvisible particles assessment. Turbidity was investigated by measuring the 205 absorbance at 3 different wavelengths. Comparable relative absorption variations were observed 206 between all conditions which was consistent with the lack of visible foam in the bags as determined 207 by visual inspection (**Table 4**). Subvisible particle formation was then analyzed by dynamic light scattering (DLS) measurements with the same stress conditions applied to the mAbs (control in 208 209 glass vial, control in plastic bag, thermal stress, and PTS). For the 4 mAbs studied (pertuzumab, pembrolizumab, trastuzumab, and cetuximab), we observed small (5-20 nm) and large (1-10 µm) 210 particles in all conditions tested (Figure 6). Our observations indicate that thermally stressed 211 212 conditions led to a higher abundance of large particles, while no significant differences were observed between the control groups and the PTS conditions. We also observed a third population 213 of particles, ranging from 100-200 nm for each mAb, exclusively in the thermally stressed group. 214

215

216 Discussion and conclusion

217 Quality issues due to biologics were highlighted by the development of trastuzumab biosimilars where batch-to-batch differences of the reference product were monitored over a long-term period 218 of time to assess the ranges of variations for key CQAs^{27–29}. A modification of the glycosylation 219 220 profile was observed; such modifications impacted the FcyRIIIa binding as well as the ADCC activity of the mAbs without any decreasing their antiproliferative activity against the HER2-221 222 positive cancer cells^{18,30}. However, in a phase III clinical trials aiming to validate the equivalence between the referent trastuzumab and SB3³¹ or ABP980³², the predefined equivalence margins to 223 224 assess the equivalence of the primary efficacy endpoints (pathological complete response – pCR) 225 were exceeded. The results of this clinical trial suggested that a potential superiority could not be 226 ruled out. A deeper analysis of the results of the clinical trial demonstrated that the pCR rates were dictated by an unexpected modification of the trastuzumab reference product for which alterations 227 228 of fucose and mannose levels were determined.

229 This prompted us to focus on some major CQA to assess the impact of PTS passage in our 230 institute with the final objective to develop analytical methods that could be utilized in hospitals 231 equipped with qualified LC-MS systems by focusing on methods without extensive mAb handling as well as with protocols that could be automatized. Intact protein analysis with SEC-nMS was 232 selected as first line method to evaluate multiple quality attributes within a single 10 min run. The 233 234 SEC-nMS method allows assessment of the drug product purity with simultaneous detection, 235 quantification, and accurate mass identification of the main product (including glycoprofile 236 monitoring) along with aggregates (HMWS) and fragments (LMWS) identification. For more 237 precise analysis of CQA related to important PTMs (glycosylation, oxidation, pyroglytamylation, and C-terminal K cleavage), complementary rpLC-MS analyses of IdES downsized mAb subunits 238 239 were performed. Altogether, the intact- and middle-level analytical pipelines demonstrated that 240 PTS did not induced major changes both in terms of size variants and for a selected series of 241 charge variants.

242 This work suggests that compared to bottom up workflows (peptide mapping), which are more 243 difficult to envision in a QC laboratory of a hospital, intact- and middle- level LC-MS analysis could 244 be proposed as "multiple attribute monitoring" methods in regulatory environments like hospital for routine analysis. The external stress induced by PTS on a mAb in its diluted version potentially 245 246 represents a more sensitive condition gathering high risks regarding the preservation of the integrity of the drug product. Hence, the orthogonal analysis of the 11 mAbs diluted in a version 247 248 ready to be injected to patients demonstrated the absence of observed impact induced by the PTS 249 as analyzed with the major CQA methods (HMWS, LMWS, glycoform profile, oxidation, etc). A comparable aggregation/degradation status and absence of alterations addressing the protein 250 251 primary structure, the glycosylation profile, the oxidation level, N-terminal cyclization and C-252 terminal K cleavage along with identical particle sizes were observed in the PTS.

253 A key confounding factor related to the risk assessment is whether air is removed from the plastic bag. Indeed, here, at the opposite to what was previously performed⁶, the air was removed from 254 255 the plastic bag to reduce as much as possible the air-liquid interface to minimize the risks of 256 oxidations. This modification in the preparation method before using the PTS seems to be the most important factor to justify using the PTS to transport the mAbs in a routine environment. 257 258 Hence, through the evaluation of the 11 mAbs, the PTS did not modify any of the mAbs. However, 259 caution should be considered to extend these results to PTS at every hospital without previous assessment of the configuration of their transportation system. If the PTS configuration highly 260 261 differs from ours, a case-by-case quality control of the PTS should be recommended. Nevertheless, the results obtained with 1 passage and 10 passages providing comparable 262 findings, it is safe to assume that PTS should not induce modification of the mAbs in respect to 263 264 the CQA if the air-liquid interface is reduced at the minimum level.

265

267 Material and methods

Materials. A total of 11 mAbs were obtained from the commercial final products provided by the ICANS hospital pharmacy. Three different batches of each one, with the 3 defined conditions, were used for the analysis following orthogonal methods for different critical quality attributes (CQAs) (Table 1 and 2).

272 *Reference mAbs*. Commercially non-diluted mAbs stored in their original glass packaging were
 273 used for analysis with 3 different batches.

274 Pneumatic stress condition. Each batch was diluted in a prefilled sodium chloride polyolefin 275 (PO) bag at a concentration of 1 mg/ml. The air was removed after dilution limiting the impact of 276 the air-water interface. The bags were then placed in the pneumatic cartridge and underwent one 277 trip through the PTS (Aerocom AC4000; Krautergersheim, France) before analysis.

Thermal stress condition. Each batch, at commercial concentration, was incubated at 50°C
during 20 days in the original glass vial before analysis to generate the thermal stress.

Acceleration measurements. As a qualification process for the PTS, we have established a cartography of stress constraints induced during the transport. An accelerometer (Volcraft[®] DL-131g, Hirschau, Germany) was fixed into a plastic bag in the cartridge used over a PTS transportation. A total of 10 travels were performed providing a characterization of all forces induced by the PTS on the bag. The average speed of the cartridge was fixed at 3.5m/s.

SEC-nMS. An ACQUITY UPLC H-class system (Waters, Manchester, UK) comprising a quaternary solvent manager, a sample manager cooled at 10 °C, a column oven maintained at room temperature and an UV detector operating at 280 nm and 214 nm hyphenated to a Synapt G2 HDMS mass spectrometer (Waters, Manchester, UK) was used for the online SEC-native MS instrumentation. Forty micrograms of mAb were loaded on the ACQUITY UPLC Protein BEH SEC column (4.6 x 150 mm, 1.7 µm particle size, 200 Å pore size) from Waters (Manchester, UK) using

an isocratic elution of 100 mM ammonium acetate (NH₄OAc) at pH 6.9 with the following flow rate
gradiant : 0.250 mL/min over 3.0 minutes, then 0.100 mL/min from 3.1 to 15.0 minutes, and finally
0.250 mL/min from 15.1 to 18.0 minutes.

The Synapt G2 HDMS was operated in positive mode with a capillary voltage of 3.0 kV while sample cone and pressure in the interface region were set to 180 V and 6 mbar, respectively. Acquisitions were performed in 50–15,000 m/z range with a 1.5 s scan time. The mass spectrometer was calibrated using singly charged ions produced by a 2 g/L solution of cesium iodide (Acros organics, Thermo Fisher Scientific, Waltham, MA USA) in 2-propanol/water (50/50 v/v). Native MS data interpretations were performed using Mass Lynx V4.1 (Waters, Manchester, UK).

Relative quantification of HMWS/LMWS by intact SEC-native was performed using the relative abundances calculated from the areas of the chromatographic peaks obtained at 280 nm. For the quantification of glycoforms at intact levels, the relative abundances were based on the intensities obtained after deconvolution of the mass spectrum. Standard deviations were calculated using biological replicates.

306

Middle level analysis using rpLC-MS. Enzymatic digestion (FabRICATOR®, Genovis, Sweden) 307 308 was performed by incubating one unit of IdeS protease per microgram of mAb. First of all, the 309 enzyme was reconstituted at four units per microliter in ultrapure water. Then, the corresponding 310 volume was added to fifty micrograms of mAb. The total volume was completed at seventy microliters by adding a buffer composed of 50 mM Na₂HPO₄ and 150 mM NaCl at pH 6.7. Finally, 311 312 the mixture was incubated at 37 °C for thirty minutes under shaking (500 rpm). In order to perform 313 a strong denaturation, thirty-three milligrams of guanidine HCI (powder) was directly added to the 314 mixture. The reduction step was performed by adding ten microliter of TCEP (tris(2-

315 carboxyethyl)phosphine) solution at 560 mM. After sixty minutes incubation at 57 °C under shaking 316 (500 rpm), the reaction was guenched by adding one microliter of TFA (trifluoroacetic acid) 317 solution. LC-MS analyses were performed using an Agilent 1200 series coupled to a maXis II 318 (Bruker) Q-TOF based mass spectrometer. A volume equivalent to five micrograms of sample preparation was injected on a BioResolve™ RP mAb 2.1 mm internal diameter and 150 mm 319 320 length, pore size 450 Å and particle size 2.7 µm, polyphenyl column (Waters, Manchester, UK) 321 set at 80 °C. The UV chromatogram was acquired with a DAD detector operating from 200 to 400 nm. Ultrapure water for mobile phase A (0.10% TFA) and acetonitrile for mobile phase B (0.08% 322 323 TFA) were used to perform the chromatographic separation. The gradient was generated at a flow 324 rate of 300 µL/min and the elution program started at 25% mobile phase B during two minutes to 325 reach 44% in thirty-eight minutes. Then, five minutes of washing step at 75% and finally fourteen 326 minutes of equilibration at 25% mobile phase B. A blank was injected between each sample under 327 the same conditions. The mass spectrometer was operated in positive mode with a capillary 328 voltage of 4,500 V and CID value was set at 70 eV. Acquisitions were performed on the mass 329 range 500-3,000 m/z. Calibration was performed using the singly charged ions produced by a 330 solution of 2 g/L caesium iodide in 2-propanol/water (50/50 v/v). Data interpretation was performed 331 by using Compass DataAnalysis 4.3 software (Bruker Daltonics). Since the molecular isotopic 332 cluster was not fully resolved, average molecular masses were measured.

Relative quantification of PTMs identified from middle level rpLC-MS analysis was performed using the relative abundances calculated from the areas of the chromatographic peaks obtained at 280 nm. For the quantification of glycoforms at the middle level, the relative abundances were based on the intensities obtained after deconvolution of the mass spectrum. Standard deviations were calculated using biological replicates.

Visible particles. Absorbance was measured with a spectrophotometer (UV-1800, Shimadzu) at 340 340, 410 and 550nm for each condition (control diluted in PO bag, pneumatic stress condition with one travel through the PTS, and thermal stress condition). Absorbance measurements were performed by aliquoting 1 ml of each sample and were expressed relative to the blank condition (sodium chloride in PO bag). A visual inspection of each bag transported with the PTS system was also implemented to detect foam.

345

346 Subvisible particles. The mAbs were stored under 3 different conditions (control in vials, 347 pneumatic stress condition with one trip through the PTS, and thermal stress condition) and then the effect of these conditions on their size was evaluated by analyzing dynamic light scattering 348 349 (DLS) measurements (Amerigo Particle Size Analyzer, Cordouan Technologies). The DLS 350 measurements were performed by directly aliguoting the samples into a cuvette exposed to an 351 external laser of 638 nm. The raw data were further analyzed by using the sparse Bayesian learning (SBL) algorithm and then the intensity average number of particles was plotted on 352 353 Graphpad Prism 8.0.

354

Statistical analysis. To evaluate significant differences between the reference monoclonal antibody (mAb) condition and the conditions of thermal or pressure thermal shock (PTS), an analysis of variance (ANOVA) test was conducted. To further examine the differences between the groups, the ANOVA test was supplemented with a Tukey test for intergroup comparisons. Differences were considered statistically significant if the p-value was less than 0.05

Acknowledgments. This study was supported by the CNRS, the University of Strasbourg, the Agence Nationale de la Recherche, the French Proteomic Infrastructure (ProFI; ANR-10-INBS-08-03), the Interdisciplinary Thematic Institute IMS (Institut du Médicament Strasbourg), as part of the ITI 2021-2028 supported by IdEx Unistra (ANR-10-IDEX-0002), SFRI-STRAT'US project

- 365 (ANR-20-SFRI-0012), and by the Institut de Cancérologie Strasbourg Europe.
- 366 Mass spectrometers were purchased through financial support of GIS IBiSA, Région Grand Est,
- the IdeX initiative of the University of Strasbourg and the French National Proteomic Infrastructure.
- 368 Authors would like to acknowledge the fruitful discussion with Aerocom^{ltd} (Krautergersheim,
- 369 France) about their PTS system which led to this research project.
- 370
- 371 Disclosure of Interest: None.
- 372 Author contributions:
- 373 Pierre Coliat have full access to all the data in the study and take responsibility for the integrity of
- the data and accuracy of the data analysis.
- 375 Concept and design: Pierre Coliat, Martin Demarchi, Xavier Pivot, Alexandre Detappe, Sarah
- 376 Cianférani
- 377 Supervision: Pierre Coliat, Sarah Cianférani, Alexandre Detappe
- 378 Statistical analysis: Pierre Coliat, Sarah Cianférani
- Administrative, technical, or material support: Dan Karouby, Stéphane Erb, Hélène Diemer
- 380 Acquisition, analysis, and interpretation of data: Pierre Coliat, Alexandre Detappe, Stéphane Erb,
- 381 Hélène Diemer, Mainak Banerjee, Chen Zhu
- 382 Manuscript draft: Pierre Coliat, Sarah Cianférani

383 Critical revision of the manuscript for important intellectual content and approval: Pierre Coliat,
384 Alexandre Detappe, Dan Karouby, Stéphane Erb, Hélène Diemer, Mainak Banerjee, Chen Zhu,
385 Martin Demarchi, Sarah Cianférani, Xavier Pivot

386

Role of the funder/Sponsor: The academic funding source (ICANS) validated the study as designed by the trial's steering committee. The data were interpreted by the trial's steering committee independently of the sponsor. The sponsor approved the manuscript and agreed to submit it for publication.

391

392 References

- Le Basle, Y., Chennell, P., Tokhadze, N., Astier, A. & Sautou, V. Physicochemical Stability of
 Monoclonal Antibodies: A Review. *J. Pharm. Sci.* **109**, 169–190 (2020).
- Mahler, H.-C., Friess, W., Grauschopf, U. & Kiese, S. Protein aggregation: Pathways, induction
 factors and analysis. *J. Pharm. Sci.* 98, 2909–2934 (2009).
- 397 3. Vlasak, J. & Ionescu, R. Fragmentation of monoclonal antibodies. *mAbs* **3**, 253–263 (2011).
- 4. FDA. Q1A(R2)-Stability-Testing-of-New-Drug-Substances-and-Products.pdf.
- 399 5. EMEA. (1049) Quality of Biotechnological Products: Stability Testing of
 400 Biotechnological/Biological Products. https://doi.usp.org/USPNF/USPNF_M99771_01_01.html
 401 doi:10.31003/USPNF M99771_01_01_01.
- 402 6. Linkuvienė, V. *et al.* Effects of Transportation of IV Bags Containing Protein Formulations Via
 403 Hospital Pneumatic Tube System: Particle Characterization by Multiple Methods. *J. Pharm. Sci.*
- **111**, 1024–1039 (2022).
- 405 7. Morar-Mitrica, S. *et al.* Development of a stable low-dose aglycosylated antibody formulation to
- 406 minimize protein loss during intravenous administration. *mAbs* **7**, 792–803 (2015).

- 8. Smith, C. *et al.* Antibody adsorption on the surface of water studied by neutron reflection. *mAbs*9, 466–475 (2017).
- 409 9. Lefebvre, G. *et al.* Surfactant Protection Efficacy at Surfaces Varies with the Nature of
 410 Hydrophobic Materials. *Pharm. Res.* 38, 2157–2166 (2021).
- 411 10. Moussa, E. M. *et al.* Immunogenicity of Therapeutic Protein Aggregates. *J. Pharm. Sci.*412 **105**, 417–430 (2016).
- 413 11. Wolf, B. *et al.* Therapeutic antibody glycosylation impacts antigen recognition and
 414 immunogenicity. *Immunology* **166**, 380–407 (2022).
- 415 12. E. Lundahl, M. L., Fogli, S., E. Colavita, P. & M. Scanlan, E. Aggregation of protein
- therapeutics enhances their immunogenicity: causes and mitigation strategies. *RSC Chem.*
- 417 *Biol.* **2**, 1004–1020 (2021).
- 418 13. Ehkirch, A. *et al.* Hyphenation of size exclusion chromatography to native ion mobility mass
- spectrometry for the analytical characterization of therapeutic antibodies and related products.
- 420 J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. **1086**, 176–183 (2018).
- 421 14. Haberger, M. *et al.* Rapid characterization of biotherapeutic proteins by size-exclusion
 422 chromatography coupled to native mass spectrometry. *mAbs* 8, 331–339 (2015).
- 423 15. Oliva, A., Llabrés, M. & Fariña, J. B. Fitting bevacizumab aggregation kinetic data with the
 424 Finke–Watzky two-step model: Effect of thermal and mechanical stress. *Eur. J. Pharm. Sci.* 77,
- 425 170–179 (2015).
- 426 16. Goyon, A. et al. Characterization of 30 therapeutic antibodies and related products by size
- 427 exclusion chromatography: Feasibility assessment for future mass spectrometry hyphenation.
- 428 *J. Chromatogr. B* **1065–1066**, 35–43 (2017).
- 429 17. Delobel, A. Glycosylation of Therapeutic Proteins: A Critical Quality Attribute. *Methods Mol.*430 *Biol. Clifton NJ* 2271, 1–21 (2021).
- 431 18. Liu, L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. *Protein Cell* 9,
 432 15–32 (2018).

- 433 19. Van Coillie, J. *et al.* Role of N-Glycosylation in FcγRIIIa interaction with IgG. *Front.*434 *Immunol.* **13**, (2022).
- 435 20. Beck, A. & Liu, H. Macro- and Micro-Heterogeneity of Natural and Recombinant IgG
 436 Antibodies. *Antibodies* 8, 18 (2019).
- 437 21. De Leoz, M. L. A. et al. NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal
- Antibodies: Comparison of Results from Diverse Analytical Methods. *Mol. Cell. Proteomics MCP* 19, 11–30 (2020).
- Beck, A. *et al.* Cutting-edge mass spectrometry characterization of originator, biosimilar
 and biobetter antibodies. *J. Mass Spectrom.* **50**, 285–297 (2015).
- 442 23. Sorensen, M. *et al.* Comparison of originator and biosimilar therapeutic monoclonal
 443 antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of444 flight mass spectrometry. *mAbs* 8, 1224–1234 (2016).
- 24. Chevreux, G., Tilly, N. & Bihoreau, N. Fast analysis of recombinant monoclonal antibodies
 using IdeS proteolytic digestion and electrospray mass spectrometry. *Anal. Biochem.* 415, 212–
 214 (2011).
- Gupta, S., Jiskoot, W., Schöneich, C. & Rathore, A. S. Oxidation and Deamidation of
 Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy. *J. Pharm. Sci.* **111**, 903–918 (2022).
- 26. Dick, L. W., Kim, C., Qiu, D. & Cheng, K.-C. Determination of the origin of the N-terminal
 pyro-glutamate variation in monoclonal antibodies using model peptides. *Biotechnol. Bioeng.*97, 544–553 (2007).
- 454 27. Lüftner, D., Lyman, G. H., Gonçalves, J., Pivot, X. & Seo, M. Biologic Drug Quality
 455 Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the
 456 Trastuzumab Biosimilar SB3. *Target. Oncol.* **15**, 467–475 (2020).
- Planinc, A. *et al.* Batch-to-batch N-glycosylation study of infliximab, trastuzumab and
 bevacizumab, and stability study of bevacizumab. *Eur. J. Hosp. Pharm.* 24, 286–292 (2017).

459 29. Batch Variation in Trastuzumab Study Affects Outcomes. *Center for Biosimilars*460 https://www.centerforbiosimilars.com/view/batch-variation-in-trastuzumab-study-affects461 outcomes (2020).

- 462 30. Pivot, X. et al. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety,
- 463 and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients
- 464 Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive

465 Early Breast Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. **36**, 968–974 (2018).

- 466 31. Pivot, X. *et al.* Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar)
- 467 versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor
- 468 receptor 2-positive breast cancer. *Eur. J. Cancer Oxf. Engl.* 1990 **120**, 1–9 (2019).
- 469 32. Minckwitz, G. von *et al.* Efficacy and safety of ABP 980 compared with reference 470 trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised,
- 471 double-blind, phase 3 trial. *Lancet Oncol.* **19**, 987–998 (2018).
- 472
- 473

1 2 Figures



- 4 5 6 Figure 1. Characterization of the pneumatic transportation system (PTS). A. Map of the PTS
- at the Institut de Cancérologie Strasbourg Europe. In red the one used for this study. B.
- Representation of the setup used for transportation of the monoclonal antibodies (mAbs). C. 7
- Characterization of the cumulative (x, y, and z axis) acceleration forces applied to the mAbs. 8
- 9



10

Figure 2 : Intact level SEC-nMS analysis. A. Intact level SEC-nMS analysis of pertuzumab.
 SEC-UV chromatograms. Insert highlight the low levels of HMWS and LMWS. B. Summary of the
 masses measured for the main drug product and aggregates/fragments in the different conditions.
 C. Quantification of HMWS and LMWS from intact SEC-native MS analysis. Histograms represent
 SEC-UV peak area integration of aggregates (HMWS, mostly dimers) and fragments (mostly Fab FC and Fab) for the 11 mAbs under investigation. <u>Red :</u> Reference mAbs ; <u>Black</u>: 1 pass-PTS
 mAbs, <u>Grey :</u> Thermally stressed mAbs.



в

	G0F/(G0F-GlcNac)	G0/G0F	G0F/G0F	G1F/G0F	G1F/G1F	G2F/G1F	
Mass (Da)) 147,897±5	147,950±3	148,094±2	148,256±3	148,419±3	148,579±4	_
Relative abundance (%)	3.0±0.8	4.2±1.2	55.9±2.6	22.2±1.5	11.0±2.3	3.8±0.9	
Reference mAb Relative abundance (%)	3.1±0.6	4.8±0.6	56.0±1.8	22.7±1.1	9.7±2.3	3.1±0.8	
T° stressed Relative abundance (%)	3.0±0.3	4.8±0.7	51.3±8.3	24.6±2.8	11.0±2.9	5.3±2.7	



Figure 3 : Glycoprofiles obtained from intact SEC-native MS analysis. A. Deconvoluted mass
 spectrum of mAb drug products (main peak) revealing glycoprofiles and corresponding histogram
 for glycoform quantification. B. Summary of the masses measured for main glycoforms. C.
 Histograms represent MS peak intensities obtained after zero-charge deconvolution of the main

- 24 glycoforms for the 11 mAbs under investigation. Of note atezolizumab is an a-glycosylated mAb
- and not represented, while cetuximab glycoprofile could not be resolved using intact SEC-nMS.
- 26 <u>Red :</u> Reference mAbs ; <u>Black :</u> 1 pass-PTS mAbs, <u>Grey :</u> Thermally stressed mAbs.



29

Figure 4 : Middle level rpLC-MS analysis of pertuzumab. A. rpLC chromatogram of
 pertuzumab obtained after IdeS digestion highlighting the LC, Fd and Fc/2 subunits. B. Summary
 of the masses measured for the different subunits. C. Deconvoluted mass spectrum and of the Fc
 subunit revealing similar glycoprofiles and subsequent glycoform quatification presented as
 histograms. D. Summary of the masses of the main glycoforms. <u>Red :</u> Reference mAbs ; <u>Black :</u>
 1 pass-PTS mAbs, <u>Grey :</u> Thermally stressed mAbs.

36



37

38 Figure 5 : Glycoprofiles of the 11 mAbs after IdeS digestion and rpLC-MS analysis. Relative

39 quantification of the glycoforms was performed after zero-charge deconvolution of MS peaks of

40 Fc/2 subunits. <u>Red :</u> Reference mAbs ; <u>Black :</u> 1 pass-PTS mAbs, <u>Grey :</u> Thermally stressed

41 *mAbs.*



Figure 6: Dynamic Light Scattering analysis of four stressed mAbs. Two distinguishable
 particle populations were observed: Small particles ranging from 5-20nm and larger particles
 ranging from 1-10µm. A third population emerged under thermally stressed conditions, consisting
 of particles ranging from 100-200nm for each monoclonal antibody.

48 49

	Commercial	_	Batches								
Name	Name	Туре	1st Batch (Exp)		2 nd Ba	tch	3 rd Batch				
Atezolizumab	TECENTRIQ®	lgG1	1162031	08/21	B0014	11/22	B0016H22	03/23			
Avelumab	BAVENCIO [®]	lgG1	213079/06	03/21	AU029984	12/21	AU030487	03/22			
Bevacizumab	MVASIS [®]	lgG1*	N7407H03	12/21	1120891	03/22	1120893	03/22			
Cetuximab	ERBITUX ®	lgG1	GOOEAJ	10/23	GOOH62	12/23	GOOMS1	03/24			
Durvalumab	IMFINZI [®]	lgG1	0121B16A	05/21	022M17B	03/23	019M17A	03/23			
Ipilimumab	YERVOY®	lgG1	ABN2184	05/22	ABE3010	11/21	ABE3010	11/21			
Nivolumab	OPDIVO [®]	lgG4	ABQ8316	06/21	ABN601	02/22	CLI10519	04/21			
Panitumumab	VECTIBIX®	lgG2	1113353	06/22	1115899	06/22	1121578A	10/22			
Pembrolizumab	KEYTRUDA®	lgG4	011736	11/21	T028333	01/22	T031876	02/22			
Pertuzumab	PERJETA [®]	lgG1	H0385H02	10/21	H0437H02	07/22	H0439H05	07/22			
Trastuzumab	TRAZIMERA®	lgG1	DE8014	02/20	N3021H02	09/22	DC5104	07/23			

51

52 **Table 1 : Summary of antibodies tested.** We tested a total of 11 monoclonal antibodies (mAbs)

using three different batches (except for ipilimumab, which was tested twice with the same batch).
The analysis was conducted prior to the expiry date of each mAb.

Critical Quality Attributes	Methods	Assessment
Aggregation/degradation	SEC n-MS	HMWS/LMWS and monomeric pics on Intact mAbs or middle-up analysis
Identification of PTM modification	SEC-nMS RPLC-MS	Glycovariants Deamidation, oxydation, disulfide bond analysis
Turbidity	UV/visible spectrophotometer	Absorbance
Subvisible particules	Dynamic Light Scattering	<1µm particles population

 Table 2 : Orthogonal analysis for Critical Quality Attributes of Monoclonal Antibodies. This table summarizes the critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and the methods used to assess them. SEC n-MS was used to assess aggregation/degradation and to identify post-translational modifications (PTMs), while RPLC-MS was used to detect glycovariants and analyze deamidation, oxidation, and disulfide bonds. Turbidity was assessed using UV/visible spectrophotometry to measure absorbance, and subvisible particles were analyzed using dynamic

light scattering to determine the population of particles less than 1 µm in size

		Fc/2 - K + 2*oxidation	Fc/2 + oxidation	Fc/2 - K + oxidation	Fc/2	Fc/2 -K	Fc/2 - K - G0F	LC	LC*	LC + PyroGlu	Fd + oxidation	Fd	Fd*	Fd + PyroGlu + oxidation	Fd + PyroGlu	Fd + PyroGlu*	
ATEZOLIZUMAB	Mass (Da)	nd	nd	23,763.6 ± 0.2	23,875.8 ± 0.4	23,747.6 ± 0.3	nd	23,364.8 ± 0.2	nd	nd	25,115.0 ±0.4	25,098.9 ± 0.3	nd	nd	25,080.8 ± 0.5	nd	
	PTS	nd	nd	1%	4%	95%	nd	100%	nd	nd	1%	97%	nd	nd	2%	nd	
	Reference mAb	nd	nd	3%	5%	92%	nd	100%	nd	nd	2%	95%	nd	nd	3%	nd	
	T° stressed	nd	nd	3%	3%	94%	nd	100%	nd	nd	5%	88%	nd	nd	7%	nd	
	Mass (Da)	nd	nd	nd	25,332.0 ± 0.2	25,203.8 ± 0.2	nd	22,788.8 ±0.2	nd	nd	nd	25,256.2 ± 0.4	nd	nd	25,238.2 ± 0.2	nd	
	PTS	nd	nd	nd	24%	76%	nd	100%	nd	nd	nd	98%	nd	nd	2%	nd	
AVELUMAB	Reference mAb	nd	nd	nd	25%	75%	nd	100%	nd	nd	nd	97%	nd	nd	3%	nd	
	T° stressed	nd	nd	nd	29%	71%	nd	100%	nd	nd	nd	94%	nd	nd	6%	nd	
	Mass (Da)	25,268.0 ± 0.2	nd	25,252.1 ± 0.2	nd	25,235.9 ± 0.4	23,791.2 ± 0.2	23,450.7 ± 0.3	nd	nd	25,961.9 ± 0.4 [+ Fd]	25,945.8 ± 0.4	nd	nd	25,927.8 ± 0.2	nd	
BEVACIZUMAB	PTS	nd	nd	1%	nd	98%	1%	100%	nd	nd	1%	97%	nd	nd	2%	nd	
DEVACIZOWIAD	Reference mAb	nd	nd	1%	nd	97%	2%	100%	nd	nd	1%	97%	nd	nd	2%	nd	
	T° stressed	2%	nd	3%	nd	87%	8%	100%	nd	nd	4%	88%	nd	nd	8%	nd	
	Mass (Da)	nd	25,380.3 ± 0.4	25,252.1 ± 0.2	25,364.1 ± 0.2	25,236.0 ± 0.4	nd	23,426.6 ± 0.3	nd	nd	27,547.3 ± 0.3						
	PTS	nd	nd	nd	24%	76%	nd	100%	nd	nd							
CETUXIMAB	Reference mAb	nd	nd	nd	25%	75%	nd	100%	nd	nd	Highly glycosylated V _H domain / coelution of species. The main one is identified by the following structure : "Fd + PyroGlu + H7N4F1"					s. 'e :	
	T° stressed	nd	1%	30%	(coelution)	69%	nd	100%	nd	nd							
	Mass (Da)	nd	nd	25,241.9 ± 0.3	nd	25,226.6 ± 0.1	nd	23,578.0 ± 0.1	nd	23,559.6 ± 0.2	nd	25,707.6 ±0.1	nd	nd	25,689.2 ± 0.2	nd	
	PTS	nd	nd	2%	nd	98%	nd	98%	nd	2%	nd	97%	nd	nd	3%	nd	
DURVALUMAB	Reference mAb	nd	nd	3%	nd	97%	nd	98%	nd	2%	nd	97%	nd	nd	3%	nd	
	T° stressed	nd	nd	5%	nd	95%	nd	96%	nd	4%	nd	82%	nd	nd	18%	nd	
	Mass (Da)	nd	nd	25,219.7 ± 0.3	nd	25,203.8 ± 0.2	nd	23,454.7 ± 0.1	nd	23,436.6 ± 0.3	nd	25,386.4 ± 0.2	nd	25,385.3 ± 0.5	25,370.1 ± 0.1	nd	
	PTS	nd	nd	2%	nd	98%	nd	97%	nd	3%	nd	7%	nd	1%	92%	nd	
IPILIMUMAB	Reference mAb	nd	nd	1%	nd	99%	nd	98%	nd	2%	nd	6%	nd	1%	93%	nd	
	T° stressed	nd	nd	3%	nd	97%	nd	96%	nd	4%	nd	6%	nd	8%	86%	nd	
NIVOLUMAB	Mass (Da)	25,251.6 ± 0.4	nd	25,235.9 ± 0.2	25,348.1 ± 0.3	25,220.0 ± 0.4	nd	23,373.5 ± 0.3	nd	23,355.5 ± 0.1	nd	nd	nd	24,565.2 ± 0.6	24,550.2 ± 0.2	nd	

	PTS	1%	nd	3%	6 (coelution)	96%	nd	95%	nd	5%	nd	nd	nd	1%	99%	nd
	Reference mAb	1%	nd	3%	6 (coelution)	96%	nd	93%	nd	7%	nd	nd	nd	1%	99%	nd
	T° stressed	1%	nd	5%	6 (coelution)	94%	nd	88%	nd	12%	nd	nd	nd	2%	98%	nd
	Mass (Da)	nd	nd	25,253.9 ±0.3	25,366.2 ± 0.3 (+ [Fc/2 - K + oxidation])	25,238.1 ±0.2	nd	23,357.6 ± 0.1	nd	nd	nd	24,918.6 ± 0.3	nd	nd	24,901.5 ± 0.2	nd
PANITUMUMAB	PTS	nd	nd	1%	2%	97%	nd	100%	nd	nd	nd	21%	nd	nd	79%	nd
	Reference mAb	nd	nd	1%	2%	97%	nd	100%	nd	nd	nd	20%	nd	nd	80%	nd
	T° stressed	nd	nd	1%	3%	96%	nd	100%	nd	nd	nd	3%	nd	nd	97%	nd
	Mass (Da)	nd	nd	25,237.7 ± 0.2	nd	25,219.7 ± 0.3	nd	23,744.1 ± 0.4	nd	23,726.1 ± 0.2	nd	25,529.9 ± 0.2	nd	25,529.3 ± 0.3	25,513.2 ± 0.4	nd
	PTS	nd	nd	3%	nd	97%	nd	96%	nd	4%	nd	7%	nd	7%	86%	nd
PEMBROLIZUMAB	Reference mAb	nd	nd	3%	nd	97%	nd	96%	nd	4%	nd	4%	nd	5%	91%	nd
	T° stressed	nd	nd	3%	nd	97%	nd	93%	nd	7%	nd	1%	nd	8%	92%	nd
	Mass (Da)	nd	nd	25,252.1 ± 0.3	nd	25,236.1 ± 0.4	nd	23,526.0 ± 0.2	nd	nd	nd	25,315.1 ± 0.4	nd	nd	25,297.0 ± 0.4	nd
	PTS	nd	nd	1%	nd	99%	nd	100%	nd	nd	nd	97%	nd	nd	3%	nd
PERTUZUMAB	Reference mAb	nd	nd	3%	nd	97%	nd	100%	nd	nd	nd	97%	nd	nd	3%	nd
	T° stressed	nd	nd	12%	nd	88%	nd	100%	nd	nd	nd	94%	nd	nd	6%	nd
	Mass (Da)	nd	nd	25,252.0 ± 0.5	25,364.2 ± 0.3 (+ [Fc/2 - K + oxidation] + [Fc/2 - K])	25,236.0 ±0.5	nd	23,442.9 ±0.4	23,443.9 ± 0.3	23,425.8 ±0.3	25,398.9 ±0.2	25,383.1 ±0.4	25,383.2 ± 0.3	nd	25,365.1 ± 0.2	25,365.3 ±0.2
TRASTUZUMAB	PTS	nd	nd	1%	3%	96%	nd	92%	8% (co	elution)	2%	96%	nd	nd	2%	nd
	Reference mAb	nd	nd	1%	3%	96%	nd	87%	13% (cc	elution)	2%	96%	nd	nd	2%	nd
	T° stressed	nd	nd	1%	2%	97%	nd	58%	20%	22% (+ [LC*])	1% (+ [Fd])	43%	44%	nd	2%	10%

Table 3 : Summary of the middle level rpLC-MS analysis on 11 mAbs

Relative absorbance (Mean +/-		550nm			410nm		340nm			
sd)	Control	Heat	Pneumatic	Control	Heat	Pneumatic	Control	Heat	Pneumatic	
TRASTUZUMAB	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0,02 (+/-0,03)	0 (+/-0)	0 (+/-0)	0,05 (+/-0,07)	
ATEZOLIZUMAB	0,01 (+/-0,02)	0,07 (+/-0,1)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0,08 (+/-0,11)	0 (+/-0)	0 (+/-0)	
AVELUMAB	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0,16 (+/-0,23)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0,01 (+/-0,01)	
BEVACIZUMAB	0,01 (+/-0,01)	0 (+/-0)	0,01 (+/-0,01)	0,01 (+/-0,01)	0 (+/-0)	0,02 (+/-0,01)	0,02 (+/-0,03)	0 (+/-0)	0,05 (+/-0,04)	
CETUXIMAB	0 (+/-0)	0 (+/-0)	0,28 (+/-0,39)	0 (+/-0)	0 (+/-0)	0,03 (+/-0,05)	0 (+/-0)	0 (+/-0)	0,46 (+/-0,65)	
DURVALUMAB	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0,06 (+/-0,08)	0 (+/-0)	0 (+/-0)	
NIVOLUMAB	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	
PANITUMUMAB	0,01 (+/-0,02)	0 (+/-0)	0,01 (+/-0,01)	0 (+/-0)	0 (+/-0)	0,01 (+/-0,01)	0,05 (+/-0,06)	0 (+/-0)	0,01 (+/-0,01)	
PEMBROLIZUMAB	0,01 (+/-0,01)	0 (+/-0)	0,01 (+/-0,01)	0,01 (+/-0,01)	0,76 (+/-1,07)	0,01 (+/-0,02)	0,01 (+/-0,01)	0 (+/-0)	0,02 (+/-0,02)	
PERTUZUMAB	0 (+/-0)	0,05 (+/-0,08)	0 (+/-0)	0 (+/-0)	0,07 (+/-0,1)	0 (+/-0)	0,03 (+/-0,04)	0,12 (+/-0,17)	0 (+/-0)	

70

71 Table 4 : Summary of turbidity analysis on 10 mAbs. Relative absorbance (Mean +/- sd) at 550nm, 410nm, and 340nm tested under 72 different conditions. Control represents mAbs in their native state, Heat represents mAbs subjected to thermal stress, and Pneumatic 73 represents mAbs subjected to pneumatic stress. The relative absorbance was measured using a UV/visible spectrophotometer at each

74 wavelength.

75 76